Study Details

Back
Study ID 1707-CL-0011
Study Title A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects with Endometriosis Associated Pelvic Pain for 12 Weeks, Followed by a 12-Week Double-blind Extension without Placebo Control, Including a 24-Week Open-Label Leuprorelin Acetate Treatment Group for Bone Mineral Density Assessment
Clinicaltrials.gov Identifier NCT01767090
Compound Name ASP1707
Medical Indication or Disease Endometriosis
Study Sponsor Astellas Pharma Europe B.V.
Collaborator Not Applicable
Study Start Date 04-Dec-2012
Study Completion Date 30-Jul-2015
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS